China National Pharmaceutical Group Corporation: Wholly-owned subsidiary China National Pharmaceutical Industry obtains the registration certificate for Slow-release Quetiapine Fumarate Tablets.

China National Pharmaceutical Group announced that its wholly-owned subsidiary China National Pharmaceutical Group Industrial Co., Ltd. has received the approval and issued a Drug Registration Certificate by the National Medical Products Administration for Quetiapine Fumarate Extended-Release Tablets. Quetiapine Fumarate Extended-Release Tablets is an atypical antipsychotic medication mainly used for controlling schizophrenia and bipolar disorder. The sales revenue of national public medical institutions for this medication is estimated to be around 442 million yuan in 2024. China National Pharmaceutical Group Industrial Co., Ltd. has invested approximately 10.407 million yuan in research and development.